Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Plavix Hearing Scheduled For Aug. 18 After Sanofi/Bristol File Preliminary Injunction

This article was originally published in The Pink Sheet Daily

Executive Summary

Apotex launch of generic clopidogrel is the “largest ‘at-risk’ infringing launch of all time,” Sanofi/Bristol court filing claims.
Advertisement

Related Content

Plavix Patent Infringement Trial Set For Jan. 22
Plavix Injunction Ruling Will Include Irreparable Harm Interpretation
Apotex Seeks $4 Bil. Bond From Sanofi/Bristol At Plavix Injunction Hearing
Plavix Label Gets CLARITY On New Indication: Will Bristol COMMIT To Marketing Effort?
Bristol Investigating Failed Plavix Settlement With Apotex
Bristol Finds Itself On The Other Side Of A Patent Suit
Plavix Rebates Aim To Stem Market Share Losses After Generic Launch
Plavix Rebates Aim To Stem Market Share Losses After Generic Launch
Apotex Launches Generic Plavix
Bristol/Sanofi's Plavix Settlement Faces Justice Department Criminal Investigation

Topics

Advertisement
UsernamePublicRestriction

Register

PS064665

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel